Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.48 |
| ▸ | F13A1 | P00488 | 8/20 | 0.48 |
| ▸ | TGM1 | P22735 | 5/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838890 | 0.90 | STS (0.51) | TGM2F13A1TGM1CHRM2CHRM4 | |
| SCHEMBL6730443 | 0.89 | PPARG (0.50) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL6733950 | 0.86 | PPARG (0.47) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL2252120 | 0.83 | TGM2 (0.63) | TGM2F13A1TGM1GPR119 | |
| SCHEMBL23923494 | 0.81 | TGM2 (0.48) | TGM2F13A1TGM1TGFBR1TGM3 | |
| SCHEMBL6790392 | 0.77 | PKM (0.65) | TGM2F13A1TGM1 | |
| SCHEMBL6375022 | 0.75 | STS (0.52) | HTR6PIK3CANR1H2GPR119TGFBR1 | |
| SCHEMBL5203030 | 0.74 | TGFBR1 (0.46) | HTR6PIK3CANR1H2GPR119TGFBR1 | |
| SCHEMBL3644720 | 0.73 | MAPT (0.62) | TGM2F13A1TGM1 | |
| SCHEMBL13765376 | 0.73 | SMN1; SMN2 (0.46) | TGM2F13A1TGM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | TGM2 1707/4885F13A1 15/4885TGM1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.